Fig. 1From: ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitorsStudy schematic. Blood-based next-generation sequencing was performed before NSCLC patients receiving immune checkpoint inhibitors. OAK and POPLAR cohort, National Cancer Center (NCC) cohort, and Shanghai and Wuhan (SH&WH) cohort were used to assess the predictive value of ctDNA-adjusted bTMBBack to article page